• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Determination of Pulmozyme (dornase alpha) stability using a kinetic colorimetric DNase I activity assay.

作者信息

Lichtinghagen Ralf

机构信息

Department of Clinical Chemistry, Medizinische Hochschule Hannover, Germany.

出版信息

Eur J Pharm Biopharm. 2006 Jul;63(3):365-8. doi: 10.1016/j.ejpb.2006.03.001. Epub 2006 May 6.

DOI:10.1016/j.ejpb.2006.03.001
PMID:16682175
Abstract

An enzymatic activity assay was developed for the determination of dornase alpha human recombinant desoxyribonuclease (DNase I) stability. The method was adapted from a colorimetric endpoint enzyme activity assay for DNase I based on the degradation of a DNA/methyl green complex. With the described modifications the kinetic measurement of enzyme activity is feasible on an automated analyzer system within a rather short time. The development of this assay was based on the need for reliable detection of a possible loss of enzyme activity after transferring the commercial therapeutic agent into sealed glass vials required for a placebo-controlled study. The measuring range of this stability test was from 0 to 3000 U/L corresponding to 0-120% of the original enzyme activity; CV values of control solutions inside the measuring range were between 3% and 5%. The enzyme activity decreased less than 15% during the observation period of 180 days. In conclusion the current kinetic assay is a reliable method for a simple time-saving determination of DNase I activity to test Pulmozyme stability as required for quality control. As dornase alpha is used for inhalation, this method also proved its reliability in testing DNase stability during aerosolization with new inhalation devices (e-flow).

摘要

相似文献

1
Determination of Pulmozyme (dornase alpha) stability using a kinetic colorimetric DNase I activity assay.
Eur J Pharm Biopharm. 2006 Jul;63(3):365-8. doi: 10.1016/j.ejpb.2006.03.001. Epub 2006 May 6.
2
Colorimetric determination of DNase I activity with a DNA-methyl green substrate.使用DNA-甲基绿底物比色法测定DNase I活性。
Anal Biochem. 1994 Nov 1;222(2):351-8. doi: 10.1006/abio.1994.1502.
3
Physicochemical compatibility of mixtures of dornase alfa and tobramycin containing nebulizer solutions.
Pediatr Pulmonol. 2009 Feb;44(2):134-41. doi: 10.1002/ppul.20955.
4
Magnesium-dependent thermostability of DNase I.
Biotechniques. 1992 Jul;13(1):64-6.
5
Physicochemical compatibility of nebulizable drug mixtures containing dornase alfa and ipratropium and/or albuterol.含多纳培南和异丙托溴铵及/或沙丁胺醇的可雾化药物混合物的物理化学相容性。
Pharmazie. 2007 Oct;62(10):760-6.
6
A novel mutation in the DNASE1 gene is related with protein instability and decreased enzyme activity in thyroid autoimmunity.DNASE1基因中的一种新型突变与甲状腺自身免疫中的蛋白质不稳定性及酶活性降低有关。
J Autoimmun. 2009 Feb;32(1):7-13. doi: 10.1016/j.jaut.2008.09.005. Epub 2008 Nov 20.
7
Rapid measurement of deoxyribonuclease I activity with the use of microchip electrophoresis based on DNA degradation.利用基于 DNA 降解的微芯片电泳快速测量脱氧核糖核酸酶 I 的活性。
Anal Biochem. 2011 Jun 1;413(1):78-9. doi: 10.1016/j.ab.2011.02.011. Epub 2011 Mar 23.
8
Study of protein conformational stability and integrity using calorimetry and FT-Raman spectroscopy correlated with enzymatic activity.利用量热法和傅里叶变换拉曼光谱法结合酶活性研究蛋白质构象稳定性和完整性。
Eur J Pharm Sci. 2008 Feb 5;33(2):177-90. doi: 10.1016/j.ejps.2007.11.002. Epub 2007 Dec 4.
9
Development of a sensitive enzyme-linked immunosorbent assay for measurement of DNase I in human serum.用于测定人血清中DNase I的灵敏酶联免疫吸附测定法的开发。
Clin Chim Acta. 2009 May;403(1-2):219-22. doi: 10.1016/j.cca.2009.03.005. Epub 2009 Mar 21.
10
Fluorometric determination of deoxyribonuclease I activity with PicoGreen.使用PicoGreen荧光法测定脱氧核糖核酸酶I活性
Anal Biochem. 2000 May 15;281(1):95-7. doi: 10.1006/abio.2000.4529.

引用本文的文献

1
Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.使用干粉共递送重组脱氧核糖核酸酶和环丙沙星治疗囊性纤维化的可吸入抗生素递送。
Pharm Res. 2010 Jan;27(1):151-60. doi: 10.1007/s11095-009-9991-2. Epub 2009 Oct 22.